GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The expansion includes a larger technical and service team and increased local procurement
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences
Subscribe To Our Newsletter & Stay Updated